{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', \"therapies. Further details on these trials can be found in the Investigator's Brochure (Section\", '5.2.2: Efficacy: combination studies).', '1.3.3.2 Emerging Safety Profile', 'Olaparib monotherapy has been associated with laboratory findings and/or clinical diagnoses,', 'generally of mild or moderate severity (CTCAE Grade 1 or 2) and generally not requiring', 'treatment discontinuation.', 'The safety profile is based on pooled data from 2901 patients with solid tumors treated with', 'olaparib monotherapy in clinical trials at the recommended dose.', 'The following adverse reactions have been identified in completed clinical trials with patients', 'receiving olaparib monotherapy where patient exposure is known. Adverse Drug Reactions', 'are organised by Medical Dictionary for Regulatory Activities (MedDRA) SOC and then by', 'MedDRA preferred term in Table 1. Within each SOC, preferred terms are arranged by', 'decreasing frequency and then by decreasing seriousness. Frequencies of occurrence of', 'adverse reactions are defined as: very common (1/10); common (1/100 to <1/10);', 'uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1000); and very rare (<1/10,000)', 'including isolated reports.', '24(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Table 1: Adverse Drug Reactions reported in Clinical Trials', 'MedDRA SOC', 'MedDRA term', 'CIOMS', 'Frequency of CTCAE', 'descriptor/', 'Grade 3 and above', 'overall frequency', '(All CTCAE', 'grades)', 'Neoplasms benign,', 'Myelodysplastic', 'Uncommon', 'Uncommon', 'malignant and', 'syndrome/acute myeloid', 'unspecified', 'leukemia', '(including', 'cysts and polyps)', 'Blood and lymphatic', 'Anemia', 'Very', 'Very common', 'system disorders', 'common', 'Neutropenia', 'Very', 'Common', 'common', 'Leukopenia', 'Very', 'Common', 'common', 'Thrombocytopenia4', 'Very', 'Common', 'common', 'Lymphopenia', 'Common', 'Uncommon', 'Immune system', 'disorders', 'Hypersensitivity', 'Uncommon', 'Rare', 'Angioedema', 'b', 'Uncommon', '-', 'Metabolism and', 'Decreased appetite', 'Very', 'Uncommon', 'nutrition disorders', 'common', 'Nervous system', 'Dizziness', 'Very', 'Uncommon', 'disorders', 'common', 'Headache', 'Very', 'Uncommon', 'common', 'Dysgeusia', 'Very', '-', 'common', 'Respiratory, thoracic', 'Cougha', 'Very', 'Uncommon', 'and mediastinal', 'common', 'disorders', 'Dyspnea', 'Very', 'Common', 'common', 'Gastrointestinal', 'Vomiting', 'Very', 'Common', 'disorders', 'common', 'Diarrhea', 'Very', 'Common', 'common', 'Nausea', 'Very', 'Common', 'common', 'Dyspepsia', 'Very', '-', 'common', 'Stomatitis', 'Common', 'Uncommon', '25(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Upper abdominal pain', 'Common', 'Uncommon', 'Skin and subcutaneous', 'Rasha', 'Common', 'Rare', 'tissue disorders', 'Dermatitis', 'Uncommon', '-', 'Erythema nodosumb', 'Rare', '-', 'General disorders', 'Fatigue (including', 'Very', 'Common', 'asthenia)', 'common', 'Investigations', 'Blood creatinine', 'Common', 'Uncommon', 'increased', 'Mean cell volume', 'Uncommon', '-', 'increased', 'a', 'Anaemia includes preferred terms (PTs) of anaemia, anaemia macrocytic, erythropenia, haematocrit', 'decreased haemoglobin decreasednormocytic anaemia and red blood cell count decreased; Cough', 'includes PTs of cough and productive cough; Dermatitis includes PTs of dermatitis and dermatitis', 'allergic; Dyspnoea includes PTs of dyspnoea and dyspnoea exertional; Hypersensitivity includes PTs of', 'drug hypersensitivity and hypersensitivity;; Leukopenia includes PTs of leukopenia and white blood cell', 'count decreased; Lymphopenia includes PTs of lymphocyte count decreased, and lymphopenia ;', 'Neutropenia includes PTs of febrile neutropenia, neutropenia, neutropenic infection, neutropenic sepsis,', 'and neutrophil count decreased; Rash includes PTs of exfoliative rash, generalised erythema, rash, rash', 'erythematous, rash macular, rash maculo-papular, rash papular and rash pruritic;; Stomatitis includes', 'PTs of aphthous ulcer, mouth ulceration and stomatitis. Thrombocytopenia includes PTs of platelet', 'count decreased, and thrombocytopenia.', 'Observed in the post-marketing setting.', 'CIOMS=Council for International Organization of Medical Sciences; CTCAE=Common Terminology', 'Criteria for Adverse Events; MedDRA=Medical Dictionary for Regulatory Activities; PT = Preferred', 'term; SOC=System organ class. MedDRA version 22.1', 'Description of selected adverse reactions', 'Myelodysplastic syndrome/acute myeloid leukaemia', 'In clinical studies, across all indications, MDS/AML occurred uncommonly in patients on', 'treatment and during the 30-day safety follow up, and <1.5% at any time after starting', 'olaparib, including cases actively solicited during the long term follow up for overall survival.', 'In patients with BRCAm platinum-sensitive relapsed ovarian cancer who had received at least', 'two prior lines of platinum chemotherapy and received study treatment until disease', 'progression (SOLO2 study, with olaparib treatment > 2 years in 45% of patients), the', 'incidence of MDS/AML was 8% in patients receiving olaparib and 4% in patients receiving', 'placebo at a follow-up of 5 years. In the olaparib arm, 9 out of 16 MDS/AML cases occurred', 'after discontinuation of olaparib during the survival follow-up. The incidence of MDS/AML', 'was observed in the context of extended overall survival in the olaparib arm and late onset of', 'MDS/AML. The risk of MDS/AML remains < 1.5% at 5 year follow up in the first-line', '26(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}